Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment

This study is testing a combination of two drugs — dalpiciclib (a cell-growth blocker) and camrelizumab (an immunotherapy drug) — for people with advanced liver cancer who have already tried immunotherapy but whose cancer continued to grow. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (the most common type of liver cancer) - Your liver cancer has reached an advanced stage (Barcelona stage C) - You previously received immunotherapy (a PD-1, PD-L1, or CTLA-4 inhibitor) but your cancer progressed - You have at least one measurable tumor - You are in reasonably good physical condition (ECOG score 0 or 1) - You have no cirrhosis or mild cirrhosis only (Child-Pugh class A) - Your blood counts and organ function meet study requirements **You may NOT be eligible if...** - Your liver cancer can be removed by surgery or treated with local ablation - You have moderate-to-severe liver cirrhosis (Child-Pugh B or C) - Your blood counts or organ function are below required levels Talk to your doctor to see if this trial is right for you.